肝移植术后替米夫定联合乙肝免疫球蛋白预防乙肝复发的研究  

Clinical Study on the Combination of Telbivudine and HBIG to Prevent Hepatitis B Recurrence after Liver Transplantation

作　　者：熊璐[1] 郭晓东[1] 高银杰[1] 张红萍[1] 章方莉[1] 张敏[1] 李进[1] 

机构地区：[1]解放军第302医院,北京100039

出　　处：《现代生物医学进展》2013年第8期1498-1499,1535,共3页Progress in Modern Biomedicine

基　　金：国家"十二五"重大专项(2012ZX10002003-004-006)

摘　　要：目的:评价在肝移植后替米夫定联合乙肝免疫球蛋白(HBIG)预防乙肝复发的临床疗效和安全性。方法:68例肝移植患者分为2组:32例患者应用拉米夫定联合HBIG预防预防乙肝的复发;36例患者应用替米夫定联合HBIG预防。观察两组患者用药干预后体内乙肝病毒DNA拷贝数(HBV DNA)、乙肝表面抗原(HBsAg)、乙肝E抗原(HBeAg)的变化以及用药过程中的不良反应。结果:拉米夫定联合HBIG组有4例患者在随访期间复发乙肝,复发率为12.5%,而替米夫定联合HBIG组未见患者复发乙肝。两组患者在治疗过程中均未见到明显的药物引起的不良反应。结论:替米夫定联合HBIG在肝移植术后预防乙肝复发中的临床疗效显著、安全性好,具有推广价值。Objective： To evaluate the clinical effects and safety of the combination of Telbivudine and HBIG to prevent Hepatitis B recurrence after liver transplantation. Methods： 68 patients after liver transplantation were divided into two groups： 32 patients were treated with Lamivudine combined with HBIG; 36 patients were treated Telbivudine combined with HBIG.. HBV DNA, HBsAg and HBeAg in all patients were observed in whole period of treatment. Adverse reactions were observed. Results： There were three patients recurring hepatitis B in Lamivudine combined with HBIG group. The recurrence rate was 12.5%. There was no patient recurring hepatitis B in Telbivudine combined with HBIG group. There were no obvious adverse reactions in all patients during treatment. Conclusion： Telbivudine combined with HBIG had a significant clinical effect and good security on preventing hepatitis B recurrence after liver transplantation, and it is worthy of promotion.

关 键 词：肝移植 替米夫定 乙肝免疫球蛋白 乙肝复发 

分 类 号：R575.3[医药卫生—消化系统] R512.6[医药卫生—内科学]